IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals (AMEX:COR) announced that new findings were reported by the University of California and the Journal of Neurosciences that reveal new information about the formation of memory in the brain and how long term potentiation (LTP) deficiencies accompany the memory loss seen during the early stages of Huntington’s disease. Drs. Lynch, Gall and their colleagues at the University of California, Irvine found that LTP structures encoding memory are defective in transgenic mouse models of Huntington’s disease. They discovered that these synaptic defects can be fully reversed through treatment with brain derived growth factor (BDNF) released at the synapses. High impact AMPAKINE® compounds increase BDNF and potentially emerge as a new treatment strategy for memory problems associated with Huntington’s disease, an incurable neurodegenerative disease.
